Harvard Pilgrim Health Care agrees to cover PCSK9 inhibitor
Harvard Pilgrim Health Care agreed to cover evolocumab (Repatha, Amgen) at a discount in the first "pay-for-performance" contract for the proprotein convertase subtilisin/kexin type 9 inhibitor, the Boston Globe reports. In August, the FDA approved evolocumab, which is an injectable medication that lowers high-density lipoprotein cholesterol.
For more, check out the link below:
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.